https://www.selleckchem.com/products/reacp53.html
38 (95% confidence interval [CI] 0.35-0.42) for BMI 18.5-22.9, 0.17 (0.15-0.19) for BMI 23-24.9, 0.1 (0.09-0.11) for BMI 25-29.9, and 0.1 (0.07-0.13) for BMI ≥30. A BMI decrease of ≥1 kg/m2 over 4 years increased the incidence of NTM-PD (aHR 1.08, 95% CI 1.01-1.16) whereas a BMI increase of ≥1 decreased the NTM-PD incidence (0.77, 95% CI 0.71-0.83).In conclusion, BMI was inversely related to development of NTM-PD and weight loss increased the risk of NTM-PD. Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was demonst
Like
Comment
Share
